Compare HIT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HIT | MDXH |
|---|---|---|
| Founded | 1964 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 68.7M |
| IPO Year | 2024 | 2021 |
| Metric | HIT | MDXH |
|---|---|---|
| Price | $0.94 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.25 | ★ $7.67 |
| AVG Volume (30 Days) | 71.2K | ★ 16.3M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,327,511.00 | N/A |
| Revenue This Year | $41.00 | $30.78 |
| Revenue Next Year | $69.63 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 70.99 | N/A |
| 52 Week Low | $0.85 | $0.40 |
| 52 Week High | $4.01 | $5.33 |
| Indicator | HIT | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 54.12 |
| Support Level | $0.93 | $0.68 |
| Resistance Level | $1.15 | $1.13 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 9.44 | 12.58 |
Health In Tech Inc is an AI-enabled insurance technology platform company that offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, it streamlines the underwriting, sales, and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs), and third-party administrators (TPAs). The company's platform serves as a marketplace for brokers, TPAs, MGUs and carriers with self-funded health insurance options for employers. The platform includes functions such as plan customization, stop-loss quoting, underwriting, claims administration, and reporting integration.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.